Evidence map›Paper›PMID 38719492›Full record

ArticleBMJ (Clinical research ed.)2024

Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.

Patrick Bidulka, David G Lugo-Palacios, Orlagh Carroll, Stephen O'Neill, Amanda I Adler, Anirban Basu, Richard J Silverwood, Jonathan W Bartlett, Dorothea Nitsch, Paul Charlton and 5 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ (Clinical research ed.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Patrick BidulkaDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK patrick.bidulka1@lshtm.ac.uk.ORCID 0000-0001-7644-2030
David G Lugo-PalaciosDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Orlagh CarrollDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Stephen O'NeillDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Amanda I AdlerDiabetes Trials Unit, The Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Headington, Oxford, UK.
Anirban BasuThe Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington School of Pharmacy, Seattle, WA, USA.
Richard J SilverwoodCentre for Longitudinal Studies, UCL Social Research Institute, University College London, London, UK.
Jonathan W BartlettDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Dorothea NitschDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Paul CharltonPatient author, Patient Research Champion Team, National Institute for Health and Care Research, London, UK.
Andrew H BriggsDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
Liam SmeethDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Ian J DouglasDepartment of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester, UK.
Richard GrieveDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Funding

University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2013 to 2026
$19.5M
NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

objectiveTo compare the effectiveness of three commonly prescribed oral antidiabetic drugs added to metformin for people with type 2 diabetes mellitus requiring second line treatment in routine clinical practice.

designCohort study emulating a comparative effectiveness trial (target trial).

settingLinked primary care, hospital, and death data in England, 2015-21.

participants75 739 adults with type 2 diabetes mellitus who initiated second line oral antidiabetic treatment with a sulfonylurea, DPP-4 inhibitor, or SGLT-2 inhibitor added to metformin.

main outcome measuresPrimary outcome was absolute change in glycated haemoglobin A

results75 739 people initiated second line oral antidiabetic treatment with sulfonylureas (n=25 693, 33.9%), DPP-4 inhibitors (n=34 464 ,45.5%), or SGLT-2 inhibitors (n=15 582, 20.6%). SGLT-2 inhibitors were more effective than DPP-4 inhibitors or sulfonylureas in reducing mean HbA

conclusionsThis emulation study of a target trial found that SGLT-2 inhibitors were more effective than sulfonylureas or DPP-4 inhibitors in lowering mean HbA

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsSulfonylurea CompoundsAdministration, OralAgedBlood PressureBody Mass IndexCohort StudiesComparative Effectiveness ResearchDrug Therapy, CombinationEnglandFemaleDipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinHypoglycemic AgentsMetforminSodium-Glucose Transporter 2 InhibitorsSulfonylurea Compounds

Identifiers

PMID38719492
PMCPMC11077536

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.